Clinical Trials

Cytek will present Full Spectrum Profiling technology at two clinical cytometry conferences in September and October, with a focus on MRD monitoring.

A post-hoc item-level analysis found domain-specific cognitive gains three months after treatment in half of evaluable active-arm participants.

Pulmovant will share Phase 2 results for inhaled sGC activator mosliciguat in PH-ILD at ERS Congress on 8 September 2026.

Topline results from the PHocus study will be presented at the European Respiratory Society Congress on 8 September, followed by an investor call.

The NASDAQ-listed RNAi oncology biotech will use net proceeds to advance its Phase 2/3 SIL204 trial in locally advanced pancreatic cancer.

The Florida biotech has secured a USPTO notice of allowance covering HCW9302 as an alopecia areata treatment, as Phase 1 data show early signs of

A late-stage development advance in Centessa's OX2R agonist pipeline triggers an $8.6 million payment to Nxera, which retains future milestone and royalty

The USPTO notice covers LSD1 inhibitor combinations for myeloid cancers, with protection expected to run to 2042 pending formal grant.

NorthStrive Biosciences will test probiotic candidates EL-22 and EL-32 in a live-mouse microgravity study under a non-binding deal with Australia's

Hungary's first robotic cardiology programme treated over 70 arrhythmia patients in its opening month, a record pace for Stereotaxis's Genesis system.

The CRISPR biotech drew an initial $75m at closing, with further tranches tied to milestones for its HAE gene-editing candidate lonvo-z.

Kala Bio will be the sole US distributor of Virotek's ophthalmology genomic testing programme under a one-year deal effective 4 September 2026.

The Lp(a)HORIZON outcomes trial in 8,323 patients met its Lp(a)-lowering goal but did not reduce the composite cardiovascular endpoint versus

New modelling data links antibiotic disc exposure to clinical benefit, strengthening the rationale for PP353 as a targeted, non-opioid therapy for vertebrogenic lumbar

The HORIZON Phase 3 trial of pelacarsen failed its primary cardiovascular endpoint, but royalty backer Royalty Pharma says it still expects a modest positive return.

Tarsus gains worldwide rights to Phase 3 oral candidate ALK-001 for Stargardt disease, a blinding inherited retinal condition with no approved therapy.

The Saudi-founded eye care group becomes the first healthcare network worldwide to receive the Surgical Review Corporation's specialist ophthalmology network

Palopegteriparatide gains a positive reimbursement recommendation in Canada for adults with chronic hypoparathyroidism inadequately controlled on standard therapy.

Phase 1 data show CLYM116 achieved near-complete APRIL suppression and a 29-day half-life, supporting quarterly dosing in IgA nephropathy.

Eledon Pharmaceuticals has submitted an IND for a registrational islet cell transplant study of tegoprubart, while reaffirming its Q4 2026 Phase 3 kidney trial start.